BridgeMD
New treatment option for Acute Ischemic Stroke
Official title Comparison of Perioperative Conscious Sedation During Endovascular Thrombectomy in Acute Ischemic Stroke
ClinicalTrials.gov ID: NCT06139692
What this study is testing
What is Dexmedetomidine?
Dexmedetomidine is an investigational medicine, being studied as a potential treatment for acute ischemic stroke.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to conduct a multicenter, prospective, randomized clinical trial to scientifically evaluate the safety and efficacy of different perioperative sedation methods during endovascular thrombectomy in acute ischemic stroke patients with large vessel occlusion in the anterior circulation.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥18 years
- Presenting with symptoms of acute ischemic stroke
- CTA or MRA confirmed occlusion of the anterior circulation (intracranial carotid artery or M1, M2 segment of the middle cerebral artery)
- Randomization finished within 24 hours of symptom onset or time last know well
- Pre-stroke mRS score ≤2
You likely can't join if
- General exclusion criteria
- Pregnant or lactating women
- Known allergy to contrast agents or nitinol devices
- Known allergy to midazolam or other benzodiazepines
- Known allergy to dexmedetomidine or its components
- Planned to receive general anesthesia for EVT
See the full eligibility criteria
- Age ≥18 years
- Presenting with symptoms of acute ischemic stroke
- CTA or MRA confirmed occlusion of the anterior circulation (intracranial carotid artery or M1, M2 segment of the middle cerebral artery)
- Randomization finished within 24 hours of symptom onset or time last know well
- Pre-stroke mRS score ≤2
- NIHSS score ≥6 at the time of randomization
- ASPECTS value ≥3
- Informed consent signed
- General exclusion criteria
- Pregnant or lactating women
- Known allergy to contrast agents or nitinol devices
- Known allergy to midazolam or other benzodiazepines
- Known allergy to dexmedetomidine or its components
- Planned to receive general anesthesia for EVT
- Uncontrolled hypertension or hypotension (defined as systolic blood pressure \>185 mmHg or \ 110 mmHg or \< 60 mmHg)
- Second-degree or third-degree heart blockage or bradyarrhythmia with a baseline heart rate lower than 50 beats/min
- Any major surgery or serious trauma within 14 days
- Known genetic or acquired bleeding diathesis (platelet count \ 50 s or international normalized ratio \> 1.7)
- Blood glucose \ 22.2 mmol/L
- Severe renal insufficiency (defined as glomerular filtration rate \ 220 mmol/L (2.5mg/dl))
- Receiving hemodialysis or peritoneal dialysis
- Life expectancy less than 1 year
- Severe agitation or seizures
- Clinical manifestations of central nervous system vasculitis
- Premorbid neurological disease or mental disorders confounding evaluation
- Unwilling to be followed up within 90 days
- Participation in other treatment assigned by chance clinical trials Imaging exclusion criteria 1\. Evidence of intracranial hemorrhage on CT or MRI 2. Cerebellar infarction with obvious space-occupying effects and...
The study team makes the final eligibility decision.
Where it's taking place
- Nanjing, None Selected, China
- Chengdu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanjing, None Selected, China; Chengdu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.